Candriam Luxembourg S.C.A. Buys 68,000 Shares of STAAR Surgical Company (STAA)
Candriam Luxembourg S.C.A. increased its stake in STAAR Surgical Company (NASDAQ:STAA) by 151.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 113,000 shares of the medical instruments supplier’s stock after buying an additional 68,000 shares during the period. Candriam Luxembourg S.C.A.’s holdings in STAAR Surgical were worth $1,220,000 as of its most recent filing with the SEC.
Other hedge funds also recently made changes to their positions in the company. Strs Ohio increased its stake in shares of STAAR Surgical by 6.2% in the second quarter. Strs Ohio now owns 27,300 shares of the medical instruments supplier’s stock valued at $294,000 after buying an additional 1,600 shares during the period. Campbell & CO Investment Adviser LLC bought a new stake in shares of STAAR Surgical during the second quarter valued at about $282,000. Creative Planning increased its stake in shares of STAAR Surgical by 22.9% in the second quarter. Creative Planning now owns 32,145 shares of the medical instruments supplier’s stock valued at $347,000 after buying an additional 6,000 shares during the period. Simplex Trading LLC increased its stake in shares of STAAR Surgical by 1,798.8% in the second quarter. Simplex Trading LLC now owns 12,779 shares of the medical instruments supplier’s stock valued at $138,000 after buying an additional 12,106 shares during the period. Finally, Goldman Sachs Group Inc. bought a new stake in shares of STAAR Surgical during the first quarter valued at about $111,000. 75.94% of the stock is currently owned by institutional investors and hedge funds.
Shares of STAAR Surgical Company (STAA) opened at 11.75 on Friday. The company’s market cap is $483.02 million. The firm’s 50-day moving average price is $10.48 and its 200 day moving average price is $9.94. STAAR Surgical Company has a 52 week low of $7.46 and a 52 week high of $11.90.
STAAR Surgical (NASDAQ:STAA) last released its quarterly earnings results on Wednesday, August 2nd. The medical instruments supplier reported ($0.01) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.04. The business had revenue of $21.90 million for the quarter, compared to analyst estimates of $22.15 million. STAAR Surgical had a negative return on equity of 8.69% and a negative net margin of 6.06%. STAAR Surgical’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same period in the prior year, the company earned ($0.02) EPS. On average, equities analysts predict that STAAR Surgical Company will post ($0.12) EPS for the current fiscal year.
Several analysts recently issued reports on the company. BidaskClub raised STAAR Surgical from a “strong sell” rating to a “sell” rating in a report on Friday. Canaccord Genuity raised their price target on STAAR Surgical from $9.00 to $11.00 and gave the stock a “hold” rating in a report on Thursday, August 3rd. Finally, Zacks Investment Research raised STAAR Surgical from a “sell” rating to a “hold” rating in a report on Wednesday, July 5th.
STAAR Surgical Company Profile
STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.
Want to see what other hedge funds are holding STAA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STAAR Surgical Company (NASDAQ:STAA).
Receive News & Ratings for STAAR Surgical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical Company and related companies with Analyst Ratings Network's FREE daily email newsletter.